Fascin在乳腺浸润性导管癌中的表达及临床意义

目的检测Fascin在乳腺浸润性导管癌中的表达情况,并探讨其临床意义。方法用免疫组织化学法检测72例乳腺浸润性导管癌及配对癌旁组织中Fascin蛋白的表达和定位,以21例乳腺良性病变（10例乳腺纤维腺瘤、5例单纯性乳腺导管上皮增生和6例乳腺小叶增生）做为对照,收集病例临床病理资料,统计分析浸润性导管癌中Fascin的表达变化及与临床病理参数的相关性。结果Fascin蛋白在浸润性导管癌、癌旁乳腺组织、乳腺良性病变中的表达阳性率分别为26-39％（19／72）、0．14％（1／72）和0％（0／21）,浸润性导管癌中Fascin蛋白的表达明显高于癌旁乳腺及乳腺良性病变（P值均〈0．01）;浸润性导管癌中Fascin的表达与临床TNM分期、肿瘤病理分级和淋巴结转移相关（P值均〈0．05）;ER或PR阴性的浸润性导管癌病例Fascin表达阳性率更高（P值均〈0．05）。结论Fascin蛋白的检测对评价乳腺浸润性导管癌生物学行为和预后具有一定的参考价值,也有望成为一个乳腺癌的治疗靶点。     

CD34和α-SMA在乳腺良恶性肿瘤间质中的表达与意义

目的 探讨CD34和α-平滑肌肌动蛋白(α-SMA)在乳腺良恶性肿瘤间质中的表达情况及其意义.方法 收集2008年1月-2011年3月在新疆医科大学附属肿瘤医院住院行手术治疗并术后经病理科诊断为乳腺导管上皮普通型增生(50例)、乳腺导管上皮非典型增生(50例)、乳腺导管原位癌(50例)及乳腺浸润性导管癌(50例)标本.应用免疫组织化学PV-9000法检测乳腺间质细胞中CD34和α-SMA的表达.结果 CD34在乳腺导管上皮普通型增生、乳腺导管上皮非典型增生、乳腺导管原位癌及乳腺浸润性导管癌间质中的表达率分别为84%、78%、48%及32%,差异有统计学意义(χ2=40.430,P=0.000),乳腺浸润性导管癌CD34阳性表达率低于乳腺导管上皮普通型增生、乳腺上皮非典型增生及乳腺导管原位癌.α-SMA在乳腺导管上皮普通型增生、乳腺导管上皮非典型增生、乳腺导管原位癌及乳腺浸润性导管癌间质中的表达率分别为28%、46%、62%及86%,差异有统计学意义(χ2=56.772,P=0.000),乳腺浸润性导管癌α-SMA阳性表达率高于乳腺导管上皮普通型增生、乳腺上皮非典型增生及乳腺导管原位癌.结论 富含α-SMA阳性表达而缺少CD34阳性表达的乳腺间质细胞更加有利于肿瘤的发生.     

Maspin在乳腺癌组织中的表达及临床病理意义

目的探讨Maspin蛋白在乳腺癌中的表达及其意义。方法采用免疫组化Envision二步法检测82例浸润性乳腺癌、16例导管内癌、20例单纯性导管上皮增生及15例正常乳腺组织中Maspin蛋白的表达情况,并分析其临床病理意义。结果Maspin在正常乳腺组织、单纯性导管上皮增生、导管内癌及浸润性乳腺癌中表达率分别为100%、90%、75%、45.1%,呈逐级下降趋势,差异有显著意义（P〈0.05）。浸润性乳腺癌组织中Maspin蛋白表达与TNM分期及淋巴结转移呈负相关,并与患者的生存时间显著相关（P〈0.05）。结论Maspin蛋白的表达在乳腺癌的发生、演变过程中起重要作用。并与患者的生存期密切相关,可作为预测乳腺癌预后的参考指标。     

Expression of telomerase genes in cancer development in atypical hyperplasia of the mammary duct

目的　观察端粒酶基因在乳腺癌前病变 乳腺导管非典型增生及乳腺癌中的表达 ,探讨其与恶性转化的关系。方法　应用原位杂交方法评价端粒酶基因hTR和hTRT在 5 0例乳腺增生组织 (其中乳腺单纯性增生 6例 ,轻度非典型增生 9例 ,中度非典型增生 12例 ,重度非典型增生 2 3例 )及 2 6例乳腺癌中的表达。结果　在乳腺导管单纯性增生组织中端粒酶基因 (hTR、hTRTmRNA)呈弱表达 (16 6 % )或表达阴性。在乳腺导管轻、中度非典型增生组织中端粒酶基因 (hTR、hTRTmRNA)呈弱表达 (2 2 2 % ,11 1% ;33 3% ,2 5 0 % ) ,在乳腺导管重度非典型增生组织中端粒酶基因 (hTR、hTRTmRNA)表达增强 (6 0 9% ,5 2 1% ) ,在乳腺癌组织中端粒酶基因(hTR、hTRTmRNA)呈较强阳性表达 (88 5 % ,80 8% )。乳腺导管重度非典型增生组织中的端粒酶基因表达与在轻中度非典型增生、乳腺浸润性导管癌组织中的表达比较差异显著 (P <0 0 5 ) ,但与导管内癌表达无显著差异(P >0 0 5 )。结论　端粒酶基因hTR、hTRT的表达与乳腺导管非典型增生细胞的恶性转化有关 ,端粒酶的重新激活可能在乳腺癌的组织发生中起作用     

PARP-1在非典型增生乳腺组织中的表达及意义

目的 探讨聚腺苷二磷酸核糖聚合酶1(PARP-1)在女性乳腺癌与各种乳腺增生性病变组织中的表达及临床意义.方法 乳腺手术后经病理学诊断证实的乳腺非典型增生78例(其中轻度非典型增生28例、中度非典型增生30例、重度非典型增生20例),另选乳腺普通型增生19例、乳腺原位癌10例、乳腺浸润性导管癌21例做为对照.用免疫组化S-P法检测PARP-1的表达.结果 在乳腺普通型增生、轻、中、重度非典型增生、原位癌和乳腺浸润性导管癌组织中,PARP-1表达的阳性率分别为26.3%、28.5%、66.7%、75.0%、80.0%和95.0%.乳腺普通型增生和轻度非典型增生与乳腺原位癌及浸润性导管癌组织中PARP-1的阳性表达率有统计学差异.中、重度非典型增生组织中PARP-1的阳性表达率与乳腺原位癌及浸润性导管癌组织差异无统计学意义.随着非典型增生程度的加重,PARP-1的阳性表达率升高,且表达强度也逐级增高.结论 对乳腺增生性疾病行PARP-1检测有利于早期发现乳腺癌.可以根据PARP-1的检测结果判断病变向乳腺癌发展的风险性.PARP-1抑制剂可能会对乳腺增生性疾病的治疗起一定的作用.     

Girdin蛋白在乳腺癌组织中的表达及临床意义

目的：探讨Girdin蛋白在乳腺癌组织中的表达及其意义。方法采用免疫组化Envision二步法检测128例浸润性乳腺癌、38例导管内癌、30例单纯性导管上皮增生及30例正常乳腺组织中Girdin蛋白的表达情况,并分析其临床病理意义。结果 Girdin蛋白在正常乳腺组织、单纯性导管上皮增生、导管内癌及浸润性乳腺癌中的阳性表达率分别为10.0%、23.3%、42.1%、51.6%,呈逐级上升趋势,差异有统计学意义（P＜0.05）。浸润性乳腺癌组织中Girdin蛋白的表达与TNM分期、淋巴结转移及人表皮生长因子受体2（HER-2）表达明显相关,并与患者的生存时间也明显相关（均P＜0.05）。结论 Girdin蛋白在乳腺癌的发生、演变过程中起重要作用。其表达与患者的生存期密切相关,可作为预测乳腺癌预后的参考指标。     

ALDH1在乳腺UDH、ADH、IDC中的表达及意义

目的：探讨ALDH1在乳腺普通导管增生、非典型导管上皮增生以及浸润性导管癌中表达及其临床意义。方法采用免疫组织化学方法对30例正常乳腺及90例乳腺导管疾病患者的ALDH1的表达进行测定。结果 ALDH1在正常、乳腺普通导管增生、不典型导管上皮增生以及浸润性导管癌中的阳性表达率为：0%、23.3%、23.3%、60%。结论乳腺浸润性导管癌患者的ALDH1的阳性率明显高于正常乳腺及其它乳腺导管疾病,提示ALDH1的阳性表达与乳腺增生至乳腺癌变的演进,且与疾病的预后有一定的关系。     

ER、PR在乳腺增生病中的定量表达及其临床意义

目的 探讨ER、PR在乳腺增生性疾病中的定量表达及其临床意义。方法 通过免疫组化SP法和定量分析技术检测乳腺单纯性增生、非典型增生（轻度、中度、重度）及导管内癌各20例中ER、PR的表达情况,并用20例正常乳腺组织作对照。结果 与正常乳腺组织、单纯性增生相比,非典型增生、导管内癌中ER、PR的表达量增加,有显著性差异（P（0．05）;ER、PR在中度非典型增生的表达量〉50％,与轻度非典型增生比较有显著差异,而与重度非典型增生、导管内癌比较差异无显著性。结论 ER、PR的异常表达可能发生在乳腺癌发生过程中的早期,其定量表达可作为早期诊断癌前病变并估计预后的有效指标。     

乳腺组织中凋亡抑制蛋白Survivin的表达差异及意义

目的:研究乳腺良、恶性病变中凋亡抑制蛋白Survivin的表达及临床病理特征的关系.方法:用免疫组化检测66例浸润性癌、10例导管内癌、26例乳腺增生(普通性导管增生18例,非典型性增生8例)、20例癌旁正常乳腺组织中Survivin的表达.结果:乳腺非典型增生、导管内癌和浸润性癌组织的Survivin水平均高于癌旁正常乳腺组织,三者间无统计学意义.浸润性癌组织中的Survivin表达与组织学分级、腋淋巴结转移和TNM分期有关,与患者年龄及肿瘤大小无关.结论:Survivin在乳腺良、恶性病变中有不同表达,可为乳腺癌的诊断、治疗和预后提供依据.     

Ezrin在乳腺癌中的表达及其临床意义

目的 探讨膜细胞骨架连接蛋白Ezrin在乳腺癌中的表达及其与临床病理参数之间的关系.方法 采用免疫组化方法检测54例乳腺浸润性导管癌组织中Ezrin蛋白的表达,选择非典型增生5例,纤维囊性乳腺病9例和男性乳腺发育症2例作为对照.结果 在乳腺浸润性导管癌中,有淋巴结转移组Ezrin的表达高于无淋巴结转移组.结论 Ezrin与乳腺浸润性导管癌的浸润和转移密切相关,可以作为预测乳腺浸润性导管癌淋巴结转移的重要肿瘤标志物.     

Breast

Effect of PTEN on the cell growth and P13K/ AKT signal pathway in Tamoxifen-resistant breast cancer cell-line LCC2;Pacilitaxel in association with gemcitabine for anthracycine-resistant advanced breast cancer;Effect of uroacitides on the cell cycle progression and the expression of Cyclin D1 of breast cancer cells ; Relationship between expression of focal adhesion kinase, tumor suppressor gene PTEN-encoding protein and biological behaviors in breast carcinoma;……     

Breast

Significance of multidisplinary surgery in chest wall resection and reconstruction for selected patients with breast cancer, Relation between c-erbBl,c-erbB2,MAPK expression and resistance to tamoxifen in breast cancer cells in vitro, Observation and clinical significance of adjuvant chemotherapy-induced amenorrhea in premenopausal breast cancer patients,Effects of Syk （L） nuclear translocation on breast cancer cell invasion,     

Breast

<正>209026 Relationship between breast cancer-related lymphoedema and VEGF-C and VGGFR-3/He Jianye (贺建业,DeptGen Surg,Anzhen Hosp,Cap Univ Med Sci, Beijing 100029)…∥Chin J Gen Surg. -2009,24(11). -900～903 Objective To study the distributionand clinicopath-ological characteristics between VEGF-C and peritumoral lymph vessels density (PlND) in breast cancer tissue,and to investigate the development and the mechanism of breast cancer-related lymphoedema(BCRL).     

Breast

<正>210378 Expression and significance of stromal CD10 and Ezrin inductal carcinoma in situ and invasive ductal carcinoma of breast/Zhang Rongju(张荣菊,Breast Cancer Research Key Lab Educat Minis Nation,Oncol Key Lab Tianjin,Tianjin Cancer Inst Cancer Hosp,Tianjin Med Univ,Tianjin 300060)…Chin J Exp Surg.-2010,27(6).-705～707     

乳腺癌术后的乳房重建

乳房重建能纠正乳房切除术后的形体畸变和减少负面情绪影响,并且不影响乳腺癌的预后及监测。是否进行重建和重建策略的制订需要个体化,必须考虑患者的形体特点、全身情况、乳腺癌治疗计划和个人喜好。乳房重建大体分为假体重建和自体组织重建。假体重建中使用盐水或硅胶假体同样安全有效;自体组织重建通常使用腹部皮瓣,其中腹部游离皮瓣技术能有效保留腹部肌肉,减少术后腹部并发症。无论是假体重建或自体组织重建都有其优缺点,都需考虑后续放疗的影响。     

Breast

<正>209169 Analysis of the treatment and prognosis of recurrent breast phyllodes tumor/Fang Yi(Dept Abdomin Surg,Oncol Cancer Hosp(Institute),Chin Acad Med Sci,Beijing 100021)…∥Chin J Oncol.-2009,31(1).-72~74Objective To explore the methods of diagnosis,treatment and prognosis for patients with recurrent breast phyllodes tumor.Methods Clinicopathological data of 26 patients with pathologically proven recurrent phyllodes tumors treated from March 1972 to June 2006 were retrospectively analyzed.Results The mean age of the 26 cases was 45 years,and the median follow-up duration was 83 months.The mean overall survival time of this series was 96 months.The primary breast phyllodes tumor was ≥5 cm in 10 cases with a recurrence rate of 60.0%(6/10 cases);<5 cm in 16 cases with a recurrence rate of 31.3% 5/16(cases).After surgical removal of the breast primary tumor,the recurrent tumor was ≥5 cm in 14 cases with a re-recurrence rate of 35.7%(5/14 cases);<5 cm was in 12 cases with a re-recurrence rate of 50.0% (6/12 cases).There was no statistically significant relationship between the(primary and reccurent)tumor size and recurrence rate(P=0.094,P=0.383)or prognosis,(P=0.142,P=0.486).The benign or malignant nature of the breast phyllodes tumor was singificantly correlated with the rate of local re-recurrence(P=0.046)and prognosis(P=0.028).     

Breast

Technique investigation of endoscopic axillary lymph node dissection by liposuction , The study on sentinel lymphatic channels by us. ing methylene blue in breast cancer patients , A study of the combination of vinorelbine and epirubicin as ncoadjuvant chemotherapy regimen in the treatment of locally advanced breast cancer , Epidermal growth factor receptor signaling pathway in tamoxifen-resistant breast cancer cells     

Breast

A retrospective study of 129 cases with immediate breast reconstruction after skin-sparing mastectomy for breast cancer; Expression of imprinted tmnor suppressor gene SLC22A18 in breast cancer; WWOX gene expression and aberrant CpG island hypermethylation of WWOX gene in breast cancer; Are there other axillary lymph node metastasis than positive sentinel lymph nodes containing micrometasrases and isolated tumor cells in patients with breast cancer.     

Breast

<正>209325 Clinical characteristics and survival in the operable breast cancer patients with different molecular subtypes/Zhang Huiming(张慧明,Dept Abdom Surg Oncol,Cancer Hosp(Inst),Chin Acad Med Sci Peking Union Med Col,Beijing 100021)…∥Chin J Oncol.-2009,31(6).-447～451Objective According to the immunohistochemical (IHC)test of ER,PR and HER-2,breast cancer can be divided into 4 different molecular subtypes:Luminal A subtype (ER or PR positive and HER-2 negative),Luminal B subtype (ER or PR positive and HER-2 positive),HER-2 sutype (ER and PR negative,HER-2 positive) and Basal-like subtype (ER,PR and HER-2 negative).This study was to analyze the clinical features of different breast cancer subtypes,and try to find the evidence of combined and individualized treatment for patients with breast cancer.Methods The data of 408 surgically treated breast cancer patients in the Cancer Hospital of Chinese Academy of Medical Sciences from January 1,2002 to December 31,2002 were collected and retrospectively analyzed.The clinicopathological features and recurrence,metastasis as well as survival of these four subtypes were compared.Results Of the 408 cases,Luminal A subtype accounted for 60.8% (248/408),Luminal Bsubtype 7.8% (32/408),HER-2 subtype 12.5%(51/408),and Basal-like subtype 18.9%(77/408).Basal-like subtype had less lymph mode metastases than other subtypes(P<0.05).HER-2 subtypes consisted of less patients aged 45 years or younger than other subtypes(P<0.05).Luminal B subtype contained less advanced cases than other subtypes(P<0.01).By August 2008,the median time of follow-up was 64 months (range,3-79 months).Fifty-eight cases presented local recurrence or metastasis,and 51 of them died of the disease.The 5-year overall survival rates (OS) for patients with Luminal A,Luminal B,Basal-like and HER-2 subtype were 89.83%,86.15%,79.85% and 86.70%,respectively.The 5-year disease-free survival (DFS) rates of the four subtypes were 83.52%,68.88% and 75.83%,respectively.The rate of local recur